Want to see JAZZ full AI Analyst Report?
Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target
1,937 Followers
JAZZ Analyst Ratings
Strong Buy
16Buy1Hold0Sell
Based on 17 analysts giving stock ratings to Jazz Pharmaceuticals in the past 3 months
JAZZ Stock 12 Month Forecast
Average Price Target
$301.82â–²(31.38% Upside)Based on 17 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $301.82 with a high forecast of $337.00 and a low forecast of $229.00. The average price target represents a 31.38% change from the last price of $229.74.
Past 12 Months12 Month ForecastJan2026Oct2026
High$337.00
Average$301.82
Low$229.00
Highest Price TargetHighest$337.00Average Price Target$301.82Lowest Price TargetLowest$229.00
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Sean Laaman | Morgan Stanley | $314→$319 | buy | 38.85%Upside | Assigned | 11/03/26 | ||
| Etzer Darout | Barclays | $271→$275 | buy | 19.70%Upside | Reiterated | 11/03/26 | ||
| Mohit Bansal | Wells Fargo | $300 | buy | 30.58%Upside | Assigned | 11/03/26 | ||
| David Amsellem | Piper Sandler | $310 | buy | 34.94%Upside | Reiterated | 11/03/26 | ||
| Gary Nachman | Canaccord Genuity | $300 | buy | 30.58%Upside | Reiterated | 11/03/26 | ||
| Leonid Timashev | RBC Capital | $296→$305 | buy | 32.76%Upside | Reiterated | 11/03/26 | ||
| Jessica Fye | J.P. Morgan | $300→$310 | buy | 34.94%Upside | Assigned | 11/03/26 | ||
| Annabel Samimy | Stifel Nicolaus | $275 | buy | 19.70%Upside | Reiterated | 11/03/26 | ||
| Joseph Thome | TD Cowen | $300 | buy | 30.58%Upside | Reiterated | 11/03/26 | ||
| Geoff Meacham | Citi | $325 | buy | 41.46%Upside | Reiterated | 11/02/26 | ||
| Jason Gerberry | Bank of America Securities | $313 | buy | 36.24%Upside | Reiterated | 11/02/26 | ||
| Ashwani Verma | UBS | $337 | buy | 46.69%Upside | Reiterated | 10/28/26 | ||
| Ami Fadia | Needham | $310 | buy | 34.94%Upside | Reiterated | 10/16/26 | ||
| Gregory Renza | Truist Financial | $281→$286 | buy | 24.49%Upside | Reiterated | 10/07/26 | ||
| Jeffrey Walch | Bernstein | $229 | hold | -0.32%Downside | Reiterated | 09/25/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Sean LaamanMorgan Stanley | BuyAssigned$314→$319 | 11/03/26 | 38.85%Upside | ||
| Etzer DaroutBarclays | BuyReiterated$271→$275 | 11/03/26 | 19.70%Upside | ||
| Mohit BansalWells Fargo | BuyAssigned$300 | 11/03/26 | 30.58%Upside | ||
| David AmsellemPiper Sandler | BuyReiterated$310 | 11/03/26 | 34.94%Upside | ||
| Gary NachmanCanaccord Genuity | BuyReiterated$300 | 11/03/26 | 30.58%Upside | ||
| Leonid TimashevRBC Capital | BuyReiterated$296→$305 | 11/03/26 | 32.76%Upside | ||
| Jessica FyeJ.P. Morgan | BuyAssigned$300→$310 | 11/03/26 | 34.94%Upside | ||
| Annabel SamimyStifel Nicolaus | BuyReiterated$275 | 11/03/26 | 19.70%Upside | ||
| Joseph ThomeTD Cowen | BuyReiterated$300 | 11/03/26 | 30.58%Upside | ||
| Geoff MeachamCiti | BuyReiterated$325 | 11/02/26 | 41.46%Upside | ||
| Jason GerberryBank of America Securities | BuyReiterated$313 | 11/02/26 | 36.24%Upside | ||
| Ashwani VermaUBS | BuyReiterated$337 | 10/28/26 | 46.69%Upside | ||
| Ami FadiaNeedham | BuyReiterated$310 | 10/16/26 | 34.94%Upside | ||
| Gregory RenzaTruist Financial | BuyReiterated$281→$286 | 10/07/26 | 24.49%Upside | ||
| Jeffrey WalchBernstein | HoldReiterated$229 | 09/25/26 | -0.32%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Jazz Pharmaceuticals
3 Months
Success Rate17/28 ratings generated profit
61%
Average Return
+1.89%
Copying Jason Gerberry's trades and holding each position for 3 Months would result in 60.71% of your transactions generating a profit, with an average return of +1.89% per trade.
1 Year
Success Rate18/22 ratings generated profit
82%
Average Return
+35.71%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +35.71% per trade.
2 Years
Success Rate19/22 ratings generated profit
86%
Average Return
+60.23%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 86.36% of your transactions generating a profit, with an average return of +60.23% per trade.
JAZZ Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 3 | 4 |
| Buy | 35 | 54 | 50 | 48 | 24 |
| Hold | 4 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 39 | 56 | 51 | 52 | 29 |
In the current month, JAZZ has received 28 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 301.82.
JAZZ Financial Forecast
High$12.69
Consensus$6.95
Low$5.30
JAZZ Earnings Forecast
Next quarter’s earnings estimate for JAZZ is $6.95 with a range of $5.30 to $12.69. The previous quarter’s EPS was -$3.88. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$1.32B
Consensus$1.28B
Low$1.23B
JAZZ Sales Forecast
Next quarter’s sales forecast for JAZZ is $1.28B with a range of $1.23B to $1.32B. The previous quarter’s sales results were $1.24B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
JAZZ Stock Forecast FAQ
What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is $301.82.
What is JAZZ’s upside potential, based on the analysts’ average price target?
Jazz Pharmaceuticals has 31.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is JAZZ a Buy, Sell or Hold?
Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
What is Jazz Pharmaceuticals’s price target?
The average price target for Jazz Pharmaceuticals is $301.82. This is based on 17 12-month price targets, issued in the past 3 months. The highest analyst price target is $337.00, the lowest forecast is $229.00. The average price target represents a 31.38% increase from the current price of $229.74.
What do analysts say about Jazz Pharmaceuticals?
Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Street analysts.
How can I buy shares of JAZZ?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
